Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Novo Nordisk A/S (NYSE:NVO) announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...

Danish diabetes and obesity giant Novo Nordisk (NOV: N) today announced headline results from REDEFINE 2, a Phase III trial ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...